Skip to main content
Contact Us
search

Author Biography

zulkarnain.pulungan@inovalon.com
Connect on LinkedIn

Zulkarnain Pulungan, PhD

AVP, Research Science and Advanced Analytics

Zulkarnain leads the designs and executions of studies on health economics and outcomes research (HEOR), predictive analytics, risk modeling, performance measurement, epidemiology, disease management evaluation, health disparity and social determinants of health.

Zulkarnain has a strong quantitative background with more than 20 years of analytic experience in designing and executing various health care studies. He has been with Inovalon for more than 9 years in various roles. Prior to joining Inovalon, he was Principal Research Scientist at Avalere, an Inovalon company where he led a team of analysts in projects including, but not limited to, HEOR studies related to heart failure, cancer, agitation in Alzheimer dementia patients, rheumatoid arthritis and pneumonia;  epidemiology studies on various diseases; developing disease progression measures; health plan performance measure improvements; predictive models related to post-acute care settings and identifying patients with agitation; and identifying social determinants of health associated with poor quality performance.

Prior to joining Inovalon, he specialized in quality measurement and improvement research at Leading Age New York and the Foundation for Long Term Care, where he developed, validated, and implemented quality measures and predictive models as part of innovative technology solutions to advance the use of data-driven decision making.

Zulkarnain received his PhD in economics from the State University of New York at Albany, where he currently teaches a graduate level course in econometrics analysis.

Authored Content

Filter

May 7, 2023
Presentation

Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured Before and After Transition to Medicare Advantage or Traditional Medicare Fee-for-Service

Teigland C, Pulungan Z, Mohammadi I, Jones B, Bilder S, Brot-Goldberg Z, Su Y, Vabson B
Accepted for presentation at ISPOR 2023. Findings available upon request. Contact us for more information.
Read More
May 3, 2023
Poster Presentation

Characteristics, Healthcare Resource Utilization, Cost, and Quality Outcomes of Medicare Beneficiaries While Commercially Insured Before and After Transition to Medicare Advantage or Traditional Medicare Fee-for-Service

Boris Vabson, Zulkarnain Pulungan, Zarek Brot-Goldberg, Yalun Su, Iman Mohammadi, Barton Jones, Christie Teigland
This study provides a first look at demographic, clinical, and social risk characteristics of individuals who select MA versus FFS while covered by commercial insurance prior to turning age 65 and compares healthcare outcomes before and after enrolling.
Read More
January 18, 2023
Peer-Reviewed Article

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease

Soileau M, Pagan F, Fasano A, Rodriguez-Cruz, Yan C, Gupta N, Teigland C, Pulungan Z, Schinkel J, Kandukuri P, Ladhani O, Siddiqui M
Complex polypharmacy regimens to manage persistent motor fluctuations result in significant pill burden for patients with advanced Parkinson’s disease (APD). This study evaluated the effectiveness of carbidopa/levodopa enteral suspension (CLES) and deep brain stimulation (DBS) on reducing pill burden in APD patients.
Read More
September 9, 2022
Presentation

Characteristics and Long-Term Health Economic Outcomes of Female Medicare Beneficiaries with Fragility Fracture Receiving Skilled Nursing Facility Care

Teigland C, Pulungan Z, Schinkel J, Agatep B, Yeh E
Accepted for presentation at American Society for Bone & Mineral Research (ASBMR) 2022. Findings available upon request. Contact us for more information.
Read More
May 15, 2022
Presentation

Identifying Disparities in Health Outcomes and the Relationship to Social Determinants of Health

Bilder S, Pulungan Z, Silverstein A, Teigland C
Accepted for presentation at Pharmaceutical Management Science Association (PMSA) 2022 Annual Conference. Findings available upon request. Contact us for more information.
Read More
April 3, 2022
Presentation

Real World Outcomes of Minimally Invasive Epicardial Surgical LAA Exclusion in Atrial Fibrillation Patients with High Risk of Stroke and Bleeding

Friedman DJ, Rose D, Calkins H, DiGiorgi P, Ramlawi B, Pulungan Z, Teigland C, Brennan M
Accepted for presentation at European Heart Rhythm Association (EHRA) 2022. Findings available upon request. Contact us for more information.
Read More
April 1, 2022
Peer-Reviewed Article

Out-of-pocket payments for Part D covered medications by Medicare Fee-for-Service beneficiaries with heart-failure with reduced ejection fraction

Fendrick AM, Djatche L, Pulungan Z, Teigland C, Yang M, Lautsch D, Hilkert R, Mentz
Out-of-pocket (OOP) drug costs for Medicare Fee-for-Service (FFS) beneficiaries with heart failure with reduced ejection fraction (HFrEF) are not well characterized. This study evaluated Part D OOP spending by Medicare beneficiaries with chronic HFrEF, stratified by those with and without a worsening HF event (WHFE).
Read More
December 7, 2021
Peer-Reviewed Article

Medication trajectory and treatment patterns in Medicare patients with heart failure with reduced ejection fraction

Mentz RJ, Lautsch D, Pulungan Z, Kim S, Hilkert R, Teigland C, Yang M, Djatche L
Although a worsening heart failure event (WHFE) is associated with poor outcomes in patients with heart failure with reduced ejection fraction (HFrEF), it is unclear how guideline-directed medical therapy (GDMT) is used in this population compared to those without WHFEs. This study evaluated treatment patterns in patients with HFrEF, both with and without WHFEs.
Read More